Clinical trial
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
NCT02932943
Study timeline
Study start (actual)2016-10-15Date precision: day
Registry last updated2019-10-11
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Depressive Disorder, Majorunresolved
Interventions
RapastinelDRUG
PlaceboDRUG
Sponsors & collaborators
Naurex, Inc, an affiliate of Allergan plclead sponsor
Mapped research locations
New YorkNew York, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1CincinnatiOhio, United States1JacksonvilleFlorida, United States1Oklahoma CityOklahoma, United States1AustinTexas, United States1RochesterNew York, United States1Las VegasNevada, United States1MemphisTennessee, United States1DaytonOhio, United States1CantonOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02932943 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.